Depression and oxidative damage to lipids

Psychoneuroendocrinology

Volumn 35, Issue 9, 2010, Pages 1356-1362

  Yager, Sarah ^a   Forlenza, Michael J ^b   Miller, Gregory E ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b DUQUESNE UNIVERSITY   (United States)

Author keywords

8 Isoprostaglandin F2 ; Atherosclerosis; Comorbidity; Depression; Lipid damage; Oxidative damage

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; LIPID;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; EDUCATION; FEMALE; HAMILTON SCALE; HUMAN; LIPID OXIDATION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROSTAGLANDIN BLOOD LEVEL; RACE; SMOKING;

ADULT; CASE-CONTROL STUDIES; DEPRESSIVE DISORDER; DINOPROST; F2-ISOPROSTANES; FEMALE; HUMANS; LIPID METABOLISM; LIPID PEROXIDATION; LIPIDS; MALE; OXIDATION-REDUCTION; OXIDATIVE STRESS; SOCIOECONOMIC FACTORS; STRESS, PHYSIOLOGICAL; YOUNG ADULT;

EID: 77956617362     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2010.03.010     Document Type: Article

References (38)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, Washington, DC. 4th ed.
2. Babior B.M. Phagocytes and oxidative stress. Am. J. Med. 2000, 109:33-44.
3. Barth J., Schumacher M., Herrmann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom. Med. 2004, 66:779-801.
4. Bhattacharyya G., Libby P. Atherosclerosis. Pathophysiology of Heart Disease: A Collaborative Project of Medical Students and Faculty 1998, 101-118. Lippincott Williams & Wilkins, Philadelphia. 2nd ed. L.S. Lilly (Ed.).
5. Bilici M., Efe H., Koroglu M.A., Uydu H.A., Bekaraglu G., Deger O. Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J. Affect Disord. 2001, 46:43-51.
6. Carney R.M., Freedland K.E., Miller G.E., Jaffe A.S. Depression as a risk factor for cardiac mortality and morbidity: a review of potential mechanisms. J. Psychosom. Res. 2002, 53:897-902.
7. Davi G., Falco A., Patrono C. Determinants of F2-isoprostane biosynthesis and inhibition in man. Chem. Phys. Lipids 2004, 128:149-163.
8. 2α and IL-6 in an elderly population with depression. Psychiatry Res. 2008, 161:59-66.
9. 2α, a marker of oxidative stress, is increased in patients with acute myocardial infarction. Free Radic. Res. 2006, 40:385-391.
10. Forlenza M.J., Miller G.E. Increased serum levels of 8-hydroxy-2'-deoxyguanosine in clinical depression. Psychosom. Med. 2006, 68:1-7.
11. Freedland K.E., Skala J.A., Carney R.M., Raczynski J.M., Taylor C.B., Mendes de Leon C.F., Ironson G., Youngblood M.E., Krishnan K.R., Veith R.C. The Depression Interview and Structured Hamilton (DISH): rationale, development, characteristics, and clinical validity. Psychosom. Med. 2002, 64:897-905.
12. Gidron Y., Russ K., Tissarchondou H., Warner J. The relation between psychological factors and DNA-damage: a critical review. Biol. Psychol. 2006, 72:291-304.
13. Glassman A.H. Depression and cardiovascular comorbidity. Dial. Clin. Neurosci. 2007, 9:9-17.
14. Halliwell B. Lipid peroxidation, antioxidants and cardiovascular disease: how should we move forward?. Cardiovasc. Res. 2000, 47:410-418.
15. Irie M., Asami S., Nagata S., Ikeda M., Miyata M., Kasai H. Psychosocial factors as a potential trigger of oxidative DNA damage in human leukocytes. Jpn. J. Cancer Res. 2001, 92:367-376.
16. Irie M., Miyata M., Kasia H. Depression and possible cancer risk due to oxidative DNA damage. J. Psychiatr. Res. 2005, 39:553-560.
17. Kessler R.C., Chiu W.T., Demler O., Walters E.E. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey replication. Arch. Gen. Psychiatry 2005, 62:617-627.
18. Lesperance F., Frasure-Smith N., ThÇroux P., Irwin M. The association between major depression and levels of soluble intercellular adhesion molecule-1, interleukin-6, and C-reactive protein in patients with recent acute coronary syndromes. Am. J. Psychiatry 2004, 161:271-277.
19. Memon R.A., Staprans I., Noor M., Holleran M., Uchida Y., Moser A.H., Feingold K.R., Grunfeld C. Infection and inflammation induce LDL oxidation in vivo. Arterioscler. Thromb. Vasc. Biol. 2000, 20:1536-1542.
20. Miller G.E., Cohen S., Herbert T.B. Pathways linking major depression and immunity in ambulatory female patients. Psychosom. Med. 1999, 61:850-860.
21. Miller G.E., Stetler C.A., Carney R.M., Freedland K.E., Banks W.A. Clinical depression and inflammatory risk markers for coronary heart disease. Am. J. Cardiol. 2002, 90:1279-1283.
22. Miller G.E., Freedland K.E., Duntley S., Carney R.M. Relation of depressive symptoms to C-reactive protein and pathogen burden (cytomegalovirus, herpes simplex virus, Epstein-Barr virus) in patients with earlier acute coronary syndromes. Am. J. Cardiol. 2005, 95:317-321.
23. Milne G., Musiek E., Morrow J. F2-Issoprostanes as markers of oxidative stress in vivo: an overview. Biomarkers 2005, 10(Suppl. 1):S10-S23.
24. Morrow J.D. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler. Thromb. Vasc. Biol. 2005, 25:279-286.
25. Musselman D.L., Evans D.L., Nemeroff C.B. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch. Gen. Psychiatry 1998, 55:580-592.
26. Paffenbarger R.S., Blair S.N., Lee I.M., Hyde R.T. Measurement of physical activity to assess health effects in free-living populations. Med. Sci. Sports Exerc. 1999, 25:60-70.
27. Patrignani P., Tacconelli S. Isoprostanes and other markers of peroxidation in atherosclerosis. Biomarkers 2005, 10(Suppl. 1):S24-S29.
28. Penninx B.W., Kritchevsky S.B., Yaffe K., Newman A.B., Simonsick E.M., Rubin S., Ferrucci L., Harris T., Pahor M. Inflammatory markers and depressed mood in older persons: results from the health, aging and body composition study. Biol. Psychiatry 2003, 54:566-572.
29. Raison C.L., Capuron L., Miller A.H. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006, 27:24-31.
30. Ranjit N., Diez-Roux A.V., Shea S., Cushman M., Seeman T., Jackson S.A., Hanyu N. Psychosocial factors and inflammation in the multi-ethnic study of atherosclerosis. Arch. Intern. Med. 2007, 167:174-181.
31. 2-isoprostanes as an index of oxidative stress in vivo. Free Radical Biol. Med. 2000, 28(4):505-513.
32. Robins L.N., Helzer J.E., Croughan J., Ratcliff K.S. National Institute of Mental Health Diagnostic Interview Schedule. Its history, characteristics, and validity. Arch. Gen. Psychiatry 1981, 38:381-389.
33. Rugulies R. Depression as a predictor for coronary heart disease. Am. J. Prev. Med. 2002, 23:51-61.
34. Sarandol A., Sarandol E., Eker S.S., Karaagac E.U., Hizli B.Z., Dirican M., Kirli S. Oxidation of apolipoprotein B-containing lipoproteins and serum paraoxonase/arylesterase activities in major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psych. 2006, 30:1103-1108.
35. 2α as a risk marker in patients with coronary heart disease. Circulation 2004, 109:843-848.
36. Spitzer R.L., Williams J.B., Kroenke K., Linzer M., deGruy F.V., Hahn S.R., Brody D., Johnson J.G. Utility of a new procedure for diagnosing mental disorders in primary care. The PRIME-MD 1000 study. JAMA 1994, 272:1749-1756.
37. VanMelle J.P., de Jong P., Spijkerman T.A., Tijssen J.G.P., Ormel J., van Veldhuisen D.J., van den Brink R.H.S., van den Berg M.P. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosom. Med. 2004, 66:814-822.
38. Zhang R., Brennan M.-L., Zhongshou S., MacPherson J.C., Schmitt D., Molenda C.E., Hazen S.L. Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. J. Biol. Chem. 2002, 277:46116-46122.